Rx Medicare

Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, announces new positive headline phase III results for NasalFent(R), the Company’s innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain.

Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain
Instanyl(R) (intranasal Fentanyl Spray) Sets New Standard In Management Of Breakthrough Cancer Pain
Instanyl Sets New Standard In Management Of Breakthrough Cancer Pain
AcelRx Announces Initiation Of Phase 2 Cancer Breakthrough Pain Program
Breakthrough Cancer Pain: First Results From Major European Patient Survey
New Therapy Options For Breakthrough Pain – European Association For Palliative Care
Disturbing Findings In Pain Relief And End-Of-Life Care For Hospitallized Children With Cancer
Treating Back Pain In Blood Marrow Cancer Patients
Acupuncture May Relieve Joint Pain Caused By Some Breast Cancer Treatments
Hypnosis Can Help Control Pain Among Women With Metastatic Breast Cancer, UB Researcher Finds
Some parents weigh ‘hastening death’ for children in extreme pain with terminal cancer
Multi-Center Data In A Large Series Of Patients Show Vertebroplasty Provides Dramatic And Lasting Pain Relief For Vertebral Compression Fractures
Third Party Reexamination Of Javelin Pharmaceuticals’ Phase III Trial Data For Ereska Yields Statistically Significant Primary Endpoint
Usual Care Often Not Consistent With Clinical Guidelines For Low Back Pain
China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug

Tags: archimedes, breaking, breakthrough, cancer, care, data, ground, nasalfent, pain, pharma, phase, showing, standard, superior

This entry was posted on Sunday, May 17th, 2009 at 7:05 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, announces new positive headline phase III results for NasalFent(R), the Company’s innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.

Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain

Related Posts

Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain

Related Posts

Leave a Reply

Rx Drug Compare

Translator

Archives

Blogroll

Recent Posts